Antitumor effects and normal tissue toxicity of 111In-labeled epidermal growth factor administered to athymic mice bearing epidermal growth factor receptor-positive human breast cancer xenografts

Journal of Nuclear Medicine

Volumn 44, Issue 9, 2003, Pages 1469-1478

  Chen, Paul ^a   Cameron, Ross ^a   Wang, Judy ^a   Vallis, Katherine A ^b,c   Reilly, Raymond M ^a,c,d  

^a TORONTO GENERAL HOSPITAL   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

111In; Auger electrons; Breast cancer; Epidermal growth factor; Epidermal growth factor receptor

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTINEOPLASTIC AGENT; CREATININE; EPIDERMAL GROWTH FACTOR RECEPTOR; GAMMA UROGASTRONE; HEMOGLOBIN; INDIUM 111; PENTETIC ACID; RADIOPHARMACEUTICAL AGENT; SODIUM CHLORIDE; 111IN DTPA HUMAN EPIDERMAL GROWTH FACTOR; 111IN-DTPA-HUMAN EPIDERMAL GROWTH FACTOR; DRUG DERIVATIVE; EPIDERMAL GROWTH FACTOR; TUMOR MARKER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUGER ELECTRON SPECTROSCOPY; BIOCHEMISTRY; BODY WEIGHT; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER REGRESSION; CELL NUCLEUS; CELL STRAIN MCF 7; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOSE RESPONSE; DRUG UPTAKE; ERYTHROCYTE; GROWTH RATE; HEMATOLOGY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; KIDNEY INJURY; LEUKOCYTE COUNT; LIVER INJURY; MICRODOSIMETRY; MOUSE; MOUSE STRAIN; NONHUMAN; PLASMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION DOSE; THROMBOCYTE COUNT; TOXICITY; TREATMENT OUTCOME; TUMOR CELL; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; ANTIBODY SPECIFICITY; BREAST TUMOR; CANCER TRANSPLANTATION; DRUG DELIVERY SYSTEM; FEMALE; METABOLIC CLEARANCE RATE; METABOLISM; METHODOLOGY; NUDE MOUSE; RADIATION RESPONSE; TISSUE DISTRIBUTION;

ANIMALS; BREAST NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, RADIATION; DRUG DELIVERY SYSTEMS; EPIDERMAL GROWTH FACTOR; FEMALE; HUMANS; METABOLIC CLEARANCE RATE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; ORGAN SPECIFICITY; PENTETIC ACID; RADIOPHARMACEUTICALS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TISSUE DISTRIBUTION; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 0142212379     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Fields Jones SM, Burris HA III. Breast cancer. In: Herfindal ET, Gourley DR, eds Textbook of Therapeutics: Drug and Disease Management. Baltimore, MD Williams & Wilkins. 1996:1533-1547.
2. Giaccone G, Linn SC, Pinedo HM. Multidrug resistance in breast cancer: mechanisms, strategies. Eur J Cancer. 1995,31A(suppl):S15-S17.
3. Klijn JGM, Berns PMJJ, Schmitz PIM, Foekens JA. The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. Endocrinol Rev. 1992;13:3-17
4. Prigent SA, Lemoine NR. The type I (EGFR-related) family of growth factor receptors and their ligands. Prog Growth Factor Res 1992;4:1-24.
5. Freiss G, Prebois C, Vignon F Control of breast cancer growth by steroids and growth factors: interactions and mechanisms Breast Cancer Res Treat. 1993;27:57-68.
6. Gullick WJ Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers. Br Med Bull, 1991;47:87-98.
7. Grunwald V, Hidalgo M. The epidermal growth factor receptor a new target for anticancer therapy. Curr Probl Cancer. 2002;26.109-164.
8. Herbst RS, Langer CJ. Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers. Semin Oncol. 2002;29:27-36.
9. Ranson M, Mansoor W, Jayson G. ZD1839 (IRESSA), a selective EGFR-TK inhibitor Expert Rev Anticancer Ther. 2002,2 161-168
10. LeMaistre CF, Meneghetti C, Howes L, Osborne CK. Targeting the EGF receptor in breast cancer treatment. Breast Cancer Res Treat. 1994;32.97-103.
11. 111In-Labeled epidermal growth factor is selectively radiotoxic to human breast cancer cells overexpressing epidermal growth factor receptor. J Nucl Med. 2000;41.429-438.
12. Fisher DA, Salido EC, Barajas L. Epidermal growth facial and the kidney. Annu Rev Physiol. 1989;51:67-80
13. Dunn WA, Hubbard AL. Receptor-mediated endocytosis of epidermal growth factor by hepatocytes in the perfused rat liver: ligand and receptor dynamics J Cell Biol. 1984,98 2148-2159
14. Waltz TM, Malm C, Nishikawa BK, Wasteson A. Transforming growth factor-alpha (TGF-alpha) in human bone marrow: demonstration of TGF-alpha in erythroblasts and eosinophilic precursor cells and of epidermal growth factor receptors in blastlike cells of myelomonocytic origin. Blood. 1995,85:2385-2392
15. Filmus J, Pollak MN, Cailleau R, Buick RN. A human breast cancer cell line with a high number of epidermal growth factor (EGF) receptors has an amplified EGF receptor gene and is growth inhibited by EGF. Biochem Biophys Res Commun. 1985;128:898-905
16. 111In for imaging human breast cancer J Nucl Med. 2000;41:903-912
17. Reilly RM, Gariépy J Investigation of factors influencing the sensitivity of tumor imaging using a receptor-binding radiopharmaceutical. J Nucl Med. 1998,39:1037-1042.
18. Motulsky HJ, Stannard P, Neubig R. Prism Version 2 0. San Diego, CA Graph-Pad Software Inc ; 1995.
19. Goddu SM, Howell RW, Rao DV Cellular dosimetry: absorbed fractions for monoenergetic electron and alpha-particle sources and S values for radionuclides uniformly distributed in different cell compartments. J Nucl Med. 1994;35:303-316.
20. Olfert ED, Cross BM, McWilliam AA, eds Guide to the Care and Use of Experimental Animals. Ottawa, Ontario, Canada: Canadian Council on Animal Care, 1993:173-176.
21. Mariani G, Bodei L, Adelstein SJ, Kassis A. Emerging roles for radiometabolic therapy of tumors based on Auger electron emission. J Nucl Med. 2000;41:1519-1521.
22. 0]octreotide: the Rotterdam experience. Semin Nucl Med. 2002;32:10-122
23. Williams LE, Duda RB, Proffitt RT, et al. Tumor uptake as a function of tumor mass: a mathematical model. J Nucl Med. 1988;29:103-109.
24. 90Y in nude mice. Int J Radiat Oncol Biol Phys. 1995,33:417-427.
25. 111In-DTPA-hEGF, chemotherapeutic agents and γ-radiation on EGFR-positive breast cancer cells Nucl Med Biol. 2002;29:693-699.
26. Howell RW, Narra VR, Sastry KSR, Rao DV. On the equivalent dose for Auger electron emitters. Radiat Res. 1993;134:71-78.
27. Watson EE, Stabin M, Bolch WE. MIRDOSE Version 3 0. Oak Ridge, TN: Oak Ridge Associated Universities; 1994.
28. Armstrong DK, Kaufmann SH, Ottaviano YL, et al. Epidermal growth factor-mediated apoptosis of MDA-MB-468 human breast cancer cells. Cancer Res. 1994;54:5280-5283.
29. Fan Z, Lu Y, Wu XP, et al. Prolonged induction of p21(Cip1/WAF1)/CDK2/ PCNA complex by epidermal growth factor receptor activation mediates ligand-induced A431 cell growth inhibition. J Cell Biol. 1995.235-242.
30. Murayama Y, Mishiraa Y. Epidermal growth factor suppresses the tumor growth of human breast cancer transplanted in nude mice. Cancer Detect Prev. 1991; 15:161-164.
31. Ward JF. The radiation-induced lesions which trigger the bystander effect. Mutat Res. 2002;499:151-154
32. Xue LY, Butler NJ, Makrigiorgos GM, Adelstein SJ, Rassis AI. Bystander effect produced by radiolabeled tumor cells in vivo [abstract]. J Nucl Med. 2002, 43(suppl):276P.
33. Behr TM, Sgouros G, Stabin MG, et al. Studies on the red marrow dosimetry in radioimmunotherapy: an experimental investigation of factors influencing the radiation-induced myelotoxicity in therapy with beta-, Auger/conversion electron-, or alpha-emitters. Clin Cancer Res. 1999;5(suppl).3031s-3043s.
34. Govindan SV, Goldenberg DM, Elsamra SE, et al. Radionuclides linked to a CD74 antibody as therapeutic agents for B-cell lymphoma: comparison of Auger electron emitters with beta-particle emitters. J Nucl Med. 2000,41:2089-2097.